Qualigen Therapeutics, Inc. received a decision from Nasdaq on September 4, 2025, regarding their compliance with the equity requirement after failing to meet the $2.5 million equity rule by July 28, 2025, but were granted an exception to demonstrate compliance by filing their next quarterly report by November 15, 2025.